COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,160 Articles (22,703 medRxiv, 8,457 bioRxiv)

Most recent first Previous |  Page 1349: Articles 13481-13490  | Next

Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada
Carazo, S., Talbot, D., Boulianne, N., Brisson, M., Gilca, R., Deceuninck, G., Brousseau, N., Drolet, M., Ouakki, M., Sauvageau, C., Barkati, S., Fortin, E., Carignan, A., De Wals, P., Skowronski, D. M., De Serres, G.
10.1101/2021.07.19.21260445 — Posted: 2021-07-22
Public Opinion and Sentiment Before and at the Beginning of COVID-19 Vaccinations in Japan: Twitter Analysis
Niu, Q., Liu, J., Nagai-Tanima, M., Aoyama, T., Masaya, K., Shinohara, Y., Matsumura, N.
10.1101/2021.07.19.21260735 — Posted: 2021-07-22
Effectiveness of Covishield vaccine in preventing Covid-19 -- A test-negative case-control study
Pramod, S., Govindan, D., Ramasubramani, P., Kar, S. S., Aggarwal, R., JIPMER vaccine effectiveness study group
10.1101/2021.07.19.21260693 — Posted: 2021-07-22
Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas
Musser, J. M., Christensen, P. A., Olsen, R. J., Long, S. W., Subedi, S., Davis, J. J., Hodjat, P., Walley, D. R., Kinskey, J. C., Gollihar, J. D.
10.1101/2021.07.19.21260808 — Posted: 2021-07-22 Discussion: Onsite
Re-emergence of respiratory syncytial virus following the COVID-19 pandemic in the United States: a modeling study
Zheng, Z., Pitzer, V. E., Shapiro, E. D., Bont, L. J., Weinberger, D. M.
10.1101/2021.07.19.21260817 — Posted: 2021-07-22
Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine
Yamamoto, S., Fukunaga, A., Tanaka, A., Takeuchi, J. S., Inoue, Y., Kimura, M., Ueda, G., Maeda, k., Mizoue, T., Ujiie, M., Sugiura, W., Ohmagari, N.
10.1101/2021.07.19.21260744 — Posted: 2021-07-22
Anaphylactic events in mRNA vaccines: a reporting case-control study
von Csefalvay, C.
10.1101/2021.07.19.21260714 — Posted: 2021-07-22
SARS-CoV-2 seroprevalence in the city of Hyderabad, India in early 2021
Laxmaiah, A., Rao, M. N., N, A., Babu, J., Kumar, U. P., Singh, P., Sharma, D., Anumalla, M. V., Kumar, S. T., R, S., Kumar, S. M., R, A., PPS, B., Kumar, C. D., P, D., S, D., Kumar, M. M., Meshram, I. I., Kumar, N. B., Sharma, P., P, R., P, R., Rao, R. K., P, R., Kumar, S. B., G, S., Rao, S. J., MV, S., F, S., Kumar, D., Rao, S. G., Tallapaka, K. B., Sowpati, D. T., Srivastava, S., Murekhar, M., Hemalatha, R., Mishra, R. K.
10.1101/2021.07.18.21260555 — Posted: 2021-07-22
COVID-19 mortality across selected states in India: the role of age structure.
Azarudeen, M. J., Dikid, T., Kurup, K., Aroskar, K., Chauhan, H., Jain, S. K., Singh, S.
10.1101/2021.07.18.21259093 — Posted: 2021-07-22
State-dependent patterns and coupling between the vaccination schedule, population mobility and the COVID epidemic outline, in the US states
Radulescu, A., Alonso, T., Reid, N., Sanchez, J.
10.1101/2021.07.18.21260708 — Posted: 2021-07-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).